{"id":34,"date":"2024-06-28T07:06:43","date_gmt":"2024-06-28T05:06:43","guid":{"rendered":"https:\/\/www.ipsen.com\/canada\/press-releases\/"},"modified":"2024-09-25T10:55:36","modified_gmt":"2024-09-25T08:55:36","slug":"communiques-de-presse","status":"publish","type":"page","link":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/","title":{"rendered":"Communiqu\u00e9s de presse"},"content":{"rendered":"    <section class=\"sub-page-banner \" style=\"background: linear-gradient(93.64deg, #224A81 2.99%, #2797D3 97.01%)\">\n        <div class=\"container content-sec\" role=\"main\" id=\"main\">\n            <nav aria-label=\"breadcrumb\">\n            <ol class=\"breadcrumb\">\n                <li class=\"breadcrumb-item\"><a href=\"https:\/\/www.ipsen.com\/canada\/fr\/\">Accueil<\/a><\/li><li class=\"breadcrumb-item active\"><a class=\"link-pointer-events-none\" href=\"#\" aria-current=\"page\">Communiqu\u00e9s de presse<\/a><\/li><\/ol>\n            <\/nav>            <h1 class=\"visible\">Communiqu\u00e9s de presse<\/h1>\n            <p class=\"visible\">Une biblioth\u00e8que compl\u00e8te de communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse.<\/p>\n        <\/div>\n    <\/section>\n\n\n\n<section class=\"media-filter\">\n    <div class=\"container media-filter-inner\">\n                <h2 class=\"media-filter-title charcoal-grey\">Retrouvez tous les communiqu\u00e9s de presse Ipsen<\/h2>\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"fr\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"pressrelease\" data-posttype=\"press_release\"\n            data-pagination=\"visible\" data-parenttermid=\"[28,30,32,33]\">\n            <div class=\"row\">\n                <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                                        <!-- media drop down -->\n                    <div class=\"media-drop-down\">\n                        <p class=\"media-drop-heading\">Filtre<\/p>\n                        <div class=\"media-dropdown-items\">\n                            <div class=\"row\">\n                                                            <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"topic-filter\">\n                                                                                <p>Sujet<\/p>\n                                                                                <div class=\"mutltiselect-dropdown topic-cat-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"topicOpt\">\n                                                                                                <option value=\"28\">Corporate                                                <\/option>\n                                                                                                <option value=\"30\">Neuroscience                                                <\/option>\n                                                                                                <option value=\"32\">Oncology                                                <\/option>\n                                                                                                <option value=\"33\">Rare Diseases                                                <\/option>\n                                                                                            <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                                                                                                                <div class=\"column-2 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"period-filter\">\n                                            <p>P\u00e9riode<\/p>\n                                          <div class=\"mutltiselect-dropdown year-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"periodOpt\">\n                                                                                            <option value=\"2025\">2025                                                                                            <option value=\"2024\">2024                                                                                            <option value=\"2023\">2023                                                                                            <option value=\"2022\">2022                                                                                            <option value=\"2021\">2021                                                                                            <option value=\"2020\">2020                                                                                            <option value=\"2019\">2019                                                                                            <option value=\"2018\">2018                                                                                            <option value=\"2017\">2017                                                                                            <option value=\"2016\">2016                                                                                        <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                \n                                                                                                            <div class=\"column-3 col-lg-4 col-md-4 \">\n                                            <div class=\"filterby-filter\">\n                                                <p>Filtrer par<\/p>\n                                                <div class=\"input-filter\">\n                                                    <input type=\"search\" name=\"filter-by\" id=\"filter-by\"\n                                                        placeholder=\"Taper un mot cl\u00e9\">\n                                                <\/div>\n                                                <div class=\"filter-by-dropdown\">\n                                                    <p class=\"recent\">recherche r\u00e9cente<\/p>\n                                                                                                        <ul class=\"filter-by-list\">\n                                                                                                            <\/ul>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                                                                                                              <\/div>\n                            <div class=\"reset-btn-div\">\n                                <a href=\"#\" class=\"reset-btn\">R\u00e9initialiser<\/a>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n                                        <!-- sorting section -->\n                    \t\t\t\t\t\t\n        <section class=\"media-filter\">\n            <div class=\"container media-filter-inner\">\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"en\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"investor-event\" data-posttype=\"event\" data-pagination=\"visible\" data-parenttermid=\"[492,493,1810,494]\">\n                    <div class=\"row\">\n                        <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                        <div class=\"sorting-sec\">\n                            <div class=\"row\">\n                                                                    <div class=\"column-1 col-xl-6 col-lg-6 col-sm-12\">\n                                        <div class=\"no-of-item-sec\">\n                                            <p>Afficher: <span id=\"start-value\">1<\/span> &#8211; <span id=\"no-of-search\">05<\/span> de <span id=\"total-count\">19<\/span>\n                                                <\/p>\n                                        <\/div>\n                                    <\/div>\n                                                                <div class=\"column-2 col-xl-6 col-lg-6 col-sm-12\">\n                                                                            <div class=\"sort-input\">\n                                            <div class=\"sort-input-inner\">\n                                            <label for=\"sorting-input\">Afficher<\/label>\n                                                                                            <select name=\"order\" aria-label=\"5\" id=\"show-list\">\n                                                    <option value=\"05\" selected>05<\/option>\n                                                    <option value=\"10\" >10<\/option>\n                                                    <option value=\"20\" >20<\/option>\n                                                    <option value=\"30\" >30<\/option>\n                                                    <option value=\"40\" >40<\/option>\n                                                    <option value=\"50\" >50<\/option>\n                                                <\/select>\n                                            <\/div>\n                                        <\/div>\n\t\t\t\t\t\t\t\t\n                                                                                                                <div class=\"sort-input-ascending\">\n                                            <div class=\"sort-input-ascending-inner\">\n                                                <label for=\"sorting-input-ascend\">Trier par<\/label>\n                                                <select name=\"sorting-input-ascend\" id=\"show-list-as\" class=\"show-list-as\">\n                                                    <option value=\"ASC\" aria-label=\"Ascendant\"  >Ascendant<\/option>\n                                                    <option value=\"DESC\" aria-label=\"Descendant\" selected>Descendant<\/option>\n                                                <\/select>\n                                            <\/div>\n                                        <\/div>                                        \n                                                                    <\/div>\n                            <\/div>\n                        <\/div>\n                        <\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\n\t\t<\/section>\n                                       \n                    <!-- Search listing include start here-->\n                    <div id=\"search-results\" class=\"story-div\">\n                        <!-- Press Release Listing start here -->\n<div class=\"story-div\" id=\"search-div\">\n\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-dipsen-pour-les-patients-atteints-dun-cancer-de-la-thyroide-differencie-refractaire-ou-inadmissibles-a-liode-radioactif-ayant-deja-e\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/07132123\/PR-final-fr-1.jpg\" alt=\"Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s\" title=\"Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#2797d3\">\n                        Oncologie                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">04 Mai 2022                            <!-- <span class=\"story-read-time\">5 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">04 Mai 2022<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-dipsen-pour-les-patients-atteints-dun-cancer-de-la-thyroide-differencie-refractaire-ou-inadmissibles-a-liode-radioactif-ayant-deja-e\/&#038;title=Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                        <a href=\"https:\/\/twitter.com\/share?text=Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Twitter.svg\" alt=\"Partager sur Twitter\" title=\"Partager sur Twitter\"\/>Twitter\n                            <\/a>\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-dipsen-pour-les-patients-atteints-dun-cancer-de-la-thyroide-differencie-refractaire-ou-inadmissibles-a-liode-radioactif-ayant-deja-e\/&#038;p=Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-dipsen-pour-les-patients-atteints-dun-cancer-de-la-thyroide-differencie-refractaire-ou-inadmissibles-a-liode-radioactif-ayant-deja-e\/\">\n                        <h5 class=\"blue-txt\">Sant\u00e9 Canada approuve le CABOMETYX\u00ae d\u2019Ipsen pour les patients atteints d\u2019un cancer de la thyro\u00efde diff\u00e9renci\u00e9 r\u00e9fractaire ou inadmissibles \u00e0 l\u2019iode radioactif ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Les donn\u00e9es de l\u2019\u00e9tude pivot de phase\u00a0III montrent que CABOMETYX\u00ae\u00a0apporte une am\u00e9lioration notable dans la survie sans progression1.<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-cabozantinib-dipsen-en-association-avec-opdivo-nivolumab-comme-traitement-de-premiere-ligne-pour-les-adultes-atteints-dadenocarcino\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/07132123\/PR-final-fr-1.jpg\" alt=\"Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique\" title=\"Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#2797d3\">\n                        Oncologie                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">20 Octobre 2021                            <!-- <span class=\"story-read-time\">5 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">20 Octobre 2021<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-cabozantinib-dipsen-en-association-avec-opdivo-nivolumab-comme-traitement-de-premiere-ligne-pour-les-adultes-atteints-dadenocarcino\/&#038;title=Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                        <a href=\"https:\/\/twitter.com\/share?text=Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Twitter.svg\" alt=\"Partager sur Twitter\" title=\"Partager sur Twitter\"\/>Twitter\n                            <\/a>\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-cabozantinib-dipsen-en-association-avec-opdivo-nivolumab-comme-traitement-de-premiere-ligne-pour-les-adultes-atteints-dadenocarcino\/&#038;p=Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-le-cabometyx-cabozantinib-dipsen-en-association-avec-opdivo-nivolumab-comme-traitement-de-premiere-ligne-pour-les-adultes-atteints-dadenocarcino\/\">\n                        <h5 class=\"blue-txt\">Sant\u00e9 Canada approuve le CABOMETYX\u00ae (cabozantinib) d\u2019Ipsen en association avec OPDIVO\u00ae (nivolumab) comme traitement de premi\u00e8re ligne pour les adultes atteints d\u2019ad\u00e9nocarcinome r\u00e9nal avanc\u00e9 ou m\u00e9tastatique<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Les donn\u00e9es de l\u2019\u00e9tude pivot de phase&nbsp;III ont montr\u00e9 que CABOMETYX\u00ae&nbsp;en association avec OPDIVO\u00ae&nbsp;pr\u00e9sente une efficacit\u00e9 sup\u00e9rieure au sunitinib pour tous les crit\u00e8res d\u2019\u00e9valuation cl\u00e9s, en r\u00e9duisant le risque de d\u00e9c\u00e8s de 40&nbsp;pour cent1&nbsp;et en donnant aux Canadiens aux prises&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-increlexmd-la-premiere-et-seule-therapie-en-facteur-de-croissance-insulinomimetique-de-type-1-igf-1-humain-recombinant-au-canada-pour-le-traitement-du-retard-severe-de-croissa\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/07132123\/PR-final-fr-1.jpg\" alt=\"Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents\" title=\"Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#7dc1e5\">\n                        Maladies rares                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">16 Mars 2021                            <!-- <span class=\"story-read-time\">10 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">16 Mars 2021<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-increlexmd-la-premiere-et-seule-therapie-en-facteur-de-croissance-insulinomimetique-de-type-1-igf-1-humain-recombinant-au-canada-pour-le-traitement-du-retard-severe-de-croissa\/&#038;title=Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                        <a href=\"https:\/\/twitter.com\/share?text=Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Twitter.svg\" alt=\"Partager sur Twitter\" title=\"Partager sur Twitter\"\/>Twitter\n                            <\/a>\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-increlexmd-la-premiere-et-seule-therapie-en-facteur-de-croissance-insulinomimetique-de-type-1-igf-1-humain-recombinant-au-canada-pour-le-traitement-du-retard-severe-de-croissa\/&#038;p=Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/sante-canada-approuve-increlexmd-la-premiere-et-seule-therapie-en-facteur-de-croissance-insulinomimetique-de-type-1-igf-1-humain-recombinant-au-canada-pour-le-traitement-du-retard-severe-de-croissa\/\">\n                        <h5 class=\"blue-txt\">Sant\u00e9 Canada approuve INCRELEXMD, la premi\u00e8re et seule th\u00e9rapie en facteur de croissance insulinomim\u00e9tique de type 1 (IGF-1) humain recombinant au Canada pour le traitement du retard s\u00e9v\u00e8re de croissance associ\u00e9 \u00e0 une maladie extr\u00eamement rare touchant les enfants et les adolescents<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">MISSISSAUGA, ON,&nbsp;le&nbsp;16 mars 2021 \/CNW\/ \u2013 Ipsen Biopharmaceuticals Canada Inc. a annonc\u00e9 aujourd\u2019hui la disponibilit\u00e9 commerciale d\u2019INCRELEXMD&nbsp;(m\u00e9casermine) pour le traitement du retard de croissance chez les enfants et les adolescents de 2 \u00e0 18&nbsp;ans atteints d\u2019une insuffisance primaire s\u00e9v\u00e8re en&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-iricor-et-luniversite-de-montreal-concluent-un-accord-avec-option-de-licence-pour-un-programme-doncologie-en-phase-de-recherche\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/07132123\/PR-final-fr-1.jpg\" alt=\"Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche\" title=\"Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#4e6e9a\">\n                        Corporate                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">04 Mai 2020                            <!-- <span class=\"story-read-time\">8 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">04 Mai 2020<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-iricor-et-luniversite-de-montreal-concluent-un-accord-avec-option-de-licence-pour-un-programme-doncologie-en-phase-de-recherche\/&#038;title=Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                        <a href=\"https:\/\/twitter.com\/share?text=Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Twitter.svg\" alt=\"Partager sur Twitter\" title=\"Partager sur Twitter\"\/>Twitter\n                            <\/a>\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-iricor-et-luniversite-de-montreal-concluent-un-accord-avec-option-de-licence-pour-un-programme-doncologie-en-phase-de-recherche\/&#038;p=Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-iricor-et-luniversite-de-montreal-concluent-un-accord-avec-option-de-licence-pour-un-programme-doncologie-en-phase-de-recherche\/\">\n                        <h5 class=\"blue-txt\">Ipsen, IRICoR et l\u2019Universit\u00e9 de Montr\u00e9al concluent un accord avec option de licence pour un programme d\u2019oncologie en phase de recherche<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Paris (France) et Montr\u00e9al (Canada), le 4 mai 2020&nbsp;\u2013 Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, IRICoR, centre pancanadien de commercialisation de la recherche en d\u00e9couverte de m\u00e9dicaments, et l\u2019Universit\u00e9 de Montr\u00e9al, ont annonc\u00e9&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-annonce-larrivee-sur-le-marche-dun-nouveau-systeme-dadministration-entierement-repense-pour-somatuline-autogel-lanreotide-injectable\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/07132123\/PR-final-fr-1.jpg\" alt=\"Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)\" title=\"Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#2797d3\">\n                        Oncologie                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">07 Janvier 2020                            <!-- <span class=\"story-read-time\">6 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">07 Janvier 2020<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-annonce-larrivee-sur-le-marche-dun-nouveau-systeme-dadministration-entierement-repense-pour-somatuline-autogel-lanreotide-injectable\/&#038;title=Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                        <a href=\"https:\/\/twitter.com\/share?text=Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Twitter.svg\" alt=\"Partager sur Twitter\" title=\"Partager sur Twitter\"\/>Twitter\n                            <\/a>\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-annonce-larrivee-sur-le-marche-dun-nouveau-systeme-dadministration-entierement-repense-pour-somatuline-autogel-lanreotide-injectable\/&#038;p=Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/fr\/press-releases\/ipsen-annonce-larrivee-sur-le-marche-dun-nouveau-systeme-dadministration-entierement-repense-pour-somatuline-autogel-lanreotide-injectable\/\">\n                        <h5 class=\"blue-txt\">Ipsen annonce l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration enti\u00e8rement repens\u00e9 pour Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide injectable)<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Mississauga, ON \u2013 Du 7\u00a0janvier\u00a02020\u00a0\u2013 Ipsen Biopharmaceuticals Canada Inc. a annonc\u00e9 aujourd\u2019hui l\u2019arriv\u00e9e sur le march\u00e9 d\u2019un nouveau syst\u00e8me d\u2019administration pour SomatulineMD\u00a0AutogelMD\u00a0(lanr\u00e9otide injectable)\u00a060, 90 et 120\u00a0mg. La nouvelle seringue pr\u00e9remplie, qui est maintenant offerte aux patients canadiens, pr\u00e9sente des caract\u00e9ristiques&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div class=\"pagination\"><span class='page-numbers current'>1<\/span><a class='page-numbers' onclick='paginationClick(2)'>2<\/a><span class='page-numbers dots'>&#8230;<\/span><a class='page-numbers' onclick='paginationClick(4)'>4<\/a><a class='next page-numbers' onclick='paginationClick(2)'><\/a><\/div><\/div>\n<!-- Press Release Listing Ends here -->\n                        <!-- Search listing include end here-->\n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-34","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Communiqu\u00e9s de presse Ipsen<\/title>\n<meta name=\"description\" content=\"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9s de presse Ipsen\" \/>\n<meta property=\"og:description\" content=\"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/\" \/>\n<meta property=\"og:site_name\" content=\"Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-25T08:55:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/\",\"url\":\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/\",\"name\":\"Communiqu\u00e9s de presse Ipsen\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#website\"},\"datePublished\":\"2024-06-28T05:06:43+00:00\",\"dateModified\":\"2024-09-25T08:55:36+00:00\",\"description\":\"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/canada\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9s de presse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/canada\/fr\/\",\"name\":\"Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/canada\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#organization\",\"name\":\"Canada\",\"url\":\"https:\/\/www.ipsen.com\/canada\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg\",\"caption\":\"Canada\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9s de presse Ipsen","description":"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9s de presse Ipsen","og_description":"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.","og_url":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/","og_site_name":"Canada","article_modified_time":"2024-09-25T08:55:36+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/","url":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/","name":"Communiqu\u00e9s de presse Ipsen","isPartOf":{"@id":"https:\/\/www.ipsen.com\/canada\/fr\/#website"},"datePublished":"2024-06-28T05:06:43+00:00","dateModified":"2024-09-25T08:55:36+00:00","description":"Retrouvez le flux des communiqu\u00e9s de presse Ipsen destin\u00e9s aux investisseurs et aux professionnels de la presse, ainsi que les coordonn\u00e9es d\u2019Ipsen pour la presse.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/canada\/fr\/communiques-de-presse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/canada\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9s de presse"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/canada\/fr\/#website","url":"https:\/\/www.ipsen.com\/canada\/fr\/","name":"Canada","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/canada\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/canada\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/canada\/fr\/#organization","name":"Canada","url":"https:\/\/www.ipsen.com\/canada\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/canada\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg","caption":"Canada"},"image":{"@id":"https:\/\/www.ipsen.com\/canada\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/pages\/34","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/comments?post=34"}],"version-history":[{"count":5,"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/pages\/34\/revisions"}],"predecessor-version":[{"id":1241,"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/pages\/34\/revisions\/1241"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/canada\/fr\/wp-json\/wp\/v2\/media?parent=34"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}